We sought to study the gene expression of chemokines and their corresponding receptors in mononuclear blood cells (MNCs) from patients with chronic heart failure (CHF), both of which were cross-sectional and longitudinal studies during therapy with intravenous immunoglobulin (IVIg). BACKGROUND We have recently demonstrated that IVIg improves left ventricular ejection fraction (LVEF) in patients with CHF. Based on the potential pathogenic role of chemokines in CHF, we hypothesized that the beneficial effect of IVIg may be related to a modulatory effect on the expression of chemokines and their receptors in MNCs.
Increasing evidence supports that inflammation is involved in the pathogenesis of chronic heart failure (CHF). Increased plasma levels and myocardial expression of inflammatory cytokines are found in patients with CHF (1, 2) and have been shown to induce myocardial dysfunction in various animal models (3, 4) . Chemokines are a family of inflammatory cytokines characterized by their ability to cause directed migration of leukocytes into inflamed tissue (5, 6) , and recent studies suggest that these mediators may be involved in the pathogenesis of CHF (7) (8) (9) . Thus, myocardial up-regulation of chemokines has been found in animal models of heart failure, possibly inducing myocardial infiltration of mononuclear blood cells (MNCs), with the development of pathologic changes characteristic of CHF (10, 11) . Chronic, low-grade inflammation with infiltrating leukocytes has also been found in the failing human myocardium (12) . By playing a crucial role in the activation and recruitment of these cells, chemokines may indirectly lead to damage and dysfunction of the cardiac muscle.
Intravenous immunoglobulin (IVIg) has been tried in a wide range of immune-mediated disorders (13) , and beneficial effects have also been suggested in acute and peripartum cardiomyopathy (14, 15) . We have recently demonstrated that IVIg improves left ventricular ejection fraction (LVEF) in patients with CHF (16) , and we hypothesized that the beneficial effect of IVIg may be partly related to the modulatory effects on the chemokine expression. To further elucidate the possible role of chemokines in the pathogenesis of CHF, we examined: 1) the gene expression of C, CC and CXC chemokines and their corresponding receptors in MNCs isolated from patients with CHF and healthy blood donors; and 2) the expression of these genes in MNCs collected during right-sided heart catheterization in patients with CHF randomized in a double-blind fashion to receive therapy with either IVIg or placebo for a total period of 26 weeks.
METHODS
Patients. The MNCs were collected from 20 patients participating in the IVIg study (Table 1) (16) . Patients were included in the IVIg study if they: 1) had chronic, stable CHF for Ͼ6 months; 2) were classified in New York Heart Association functional class II to III; 3) had LVEF Ͻ40%; 4) had no changes in medication during the last three months; and 5) were receiving optimal medical treatment. Patients were not included if they had: 1) evidence of myocardial infarction or unstable angina during the last six months, or 2) significant concomitant disease, such as infections, pulmonary disease or connective tissue disease. The conventional cardiovascular treatment was not changed in any of the patients during the study. The etiology of CHF was classified as coronary artery disease (n ϭ 10) or idiopathic dilated cardiomyopathy (n ϭ 10). For comparison, MNCs were isolated from peripheral venous blood drawn from the antecubital vein in 10 healthy gender-and age-matched control subjects. The study was approved by the Regional Ethics Committee and conformed to the Declaration of Helsinki. Written, informed consent was obtained from each patient. Preparation of IVIg. Octagam (Octapharma, Vienna, Austria), produced from fresh-frozen plasma collected from Norwegian blood banks, was dispensed in sterile water containing 10% maltose (final IgG concentration of 50 g/l) (16) . Design of the IVIg study. The study design has previously been described (16) . Briefly, after baseline measurements, the patients were randomized to either IVIg or placebo (5% glucose) in a double-blind fashion and stratified according to etiology (i.e., coronary artery disease or idiopathic dilated cardiomyopathy). Either IVIg or an equal volume of placebo was given as induction therapy (one daily infusion of 0.4 g/kg body weight for five days), and thereafter as a monthly infusion (0.4 g/kg for five months). Baseline measurements were repeated at the end of the study (26 weeks, four weeks after the last IVIg or placebo infusion). At baseline and at the end of the study, LVEF was assessed by electrocardiographically synchronized, gated radionuclide ventriculography at rest (16) , and blood samples from the pulmonary artery and coronary sinus were collected during right-sided heart catheterization. Plasma samples from peripheral venous blood were obtained at baseline and after one, three and five months. In addition, four patients with CHF (not included in the IVIg study) underwent leftand right-sided heart catheterization to examine the differences in chemokine gene expression between the femoral vein, femoral artery and pulmonary artery, and in the femoral vein between the start and end of the catheterization procedure. Collection and storage of plasma were performed as previously described (16) . Ribonuclease protection assay (RPA). The MNCs were obtained from heparinized blood by Isopaque-Ficoll (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) through gradient centrifugation within 45 min. Total ribonucleic acid (RNA) was extracted from frozen cells using RNeasy columns (QIAGEN, Hilden, Germany) and stored in RNA storage solution (Ambion, Austin, Texas) at Ϫ80°C until used. Multiprobe template sets (hCK5, hCR5 and hCR6) were available with reagents for in vitro transcription and RPA (RiboQuant; Pharmingen, San Diego, California). The RPA was used for the detection and quantification of messenger RNA (mRNA) species, as previously described (9 Data are presented as the mean value Ϯ SEM or number of patients or subjects. ACE ϭ angiotensin-converting enzyme; ANP ϭ atrial natriuretic peptide; CAD ϭ coronary artery disease; IDCM ϭ idiopathic dilated cardiomyopathy; IVIg ϭ intravenous immunoglobulin; NYHA ϭ New York Heart Association. 
RESULTS

Changes in MNC's chemokine gene expression in human CHF.
Of the eight chemokine genes tested, seven were detected with RPA in patients with CHF and healthy blood donors (Fig. 1) . The gene expression of MIP-1␣ (ϳ21-fold), MIP-1␤ (ϳ10-fold) and IL-8 (ϳ36-fold), but not regulated upon activation, normally T cell expressed and secreted (RANTES), was markedly increased in the patients compared with the healthy control subjects (Fig. 1) . The other chemokines were detected at very low levels in both patients with CHF and control subjects. In the patients with CHF, the mRNA level of MIP-1␣ was significantly higher in MNCs from arterial blood compared with cells from venous blood (ϳ24% increase, p Ͻ 0.05). Moreover, gene expression of this chemokine was also significantly increased in cells from the coronary sinus compared with those from the pulmonary artery (ϳ30% increase, p Ͻ 0.01). Furthermore, there were no differences between peripheral and central venous blood in patients with CHF and no significant induction of chemokine genes during the catheterization procedure (data not shown). (Fig. 2) . In addition, CCR2 (i.e., the MCP-1 receptor) and CX 3 CR (the fractalkine receptor) showed enhanced gene expression in CHF (Fig. 2) . In contrast, gene expression of chemokine receptors involved in constitutive lymphocyte homing (i.e., CXCR5 and CCR7) (6) was significantly reduced in patients with CHF compared with healthy blood donors (Fig. 2) . Effect of IVIg therapy on chemokine and chemokine receptor expression. Next, we examined whether IVIg could modulate the enhanced expression of chemokines and their corresponding receptors in patients with CHF receiving IVIg (n ϭ 10) or placebo (n ϭ 10) for 26 weeks (see Methods section). The interaction between the time of observation and chemokine gene expression was significant for MIP-1␣ (p Ͻ 0.001) and MIP-1␤ (p Ͻ 0.01), but no consistent interaction was seen for IL-8 gene expression (p ϭ 0.08). Gene expression of MIP-1␣ and MIP-1␤ significantly decreased during IVIg treatment, but not during placebo; this decrease was seen in all but one patient (Fig. 3) . We also measured plasma levels of MIP-1␣, MIP-1␤ and IL-8 at baseline and after one, three and five months of therapy. The interaction between the time of observation and chemokine plasma levels was significant for MIP-1␣ (p Ͻ 0.001), MIP-1␤ (p Ͻ 0.001) and IL-8 (p Ͻ 0.05). Although these chemokines tended to increase in the placebo group, they significantly decreased during IVIg therapy, resulting in significant differences in changes between the groups for MIP-1␣ and MIP-1␤ (Fig. 4) . Moreover, there was also a significant interaction between the time of observation and chemokine receptor gene expression; CCR1 (p Ͻ 0.001), CCR5 (p Ͻ 0.01) and CXCR1 (p Ͻ 0.05). Thus, the decrease in chemokine levels Damås et al.
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IVIg Suppresses Enhanced Chemokine Expression in CHF was accompanied by a significant decrease in their receptor levels on MNCs (i.e., CCR1, CCR5 and CXCR1) during IVIg, but not placebo, treatment (Fig. 5 ).
Chemokine and chemokine receptor gene expression in MNCs in relation to LVEF. Gene expression of MIP-1␣
(r ϭ Ϫ0.66, p Ͻ 0.01), MIP-1␤ (r ϭ Ϫ0.52, p Ͻ 0.05) and their common receptor CCR1 (r ϭ Ϫ0.64, p Ͻ 0.01) was inversely correlated with LVEF at baseline. We have previously shown a significant increase in LVEF (five ejection fraction units) after IVIg treatment, but not after placebo, in these patients with CHF (16) . Importantly, this increase in LVEF was significantly correlated with the decrease in MIP-1␣ mRNA levels during IVIg (Fig. 6 ).
DISCUSSION
Increased chemokine expression has been detected during inflammation in most organs, resulting in a selective recruitment of leukocyte subpopulations into inflamed tissue (5, 6) . To the best of our knowledge, the present study is the first to show markedly altered gene expression of several chemokines and their corresponding receptors in MNCs from patients with CHF, and notably, these abnormalities were significantly modulated in a normal direction during IVIg therapy. As for MIP-1␣ levels, down-regulation was significantly correlated with improved LVEF during such therapy. These findings support a role for abnormal chemokine activation in the pathogenesis of CHF and suggest that IVIg may modulate such activity. Damås et al.
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IVIg Suppresses Enhanced Chemokine Expression in CHF heart circulation, respectively. Recent reports indicate that chemokines are involved in the migration of MNCs into the cardiovascular system in various disorders, such as atherosclerosis and myocarditis (5, 6, 11) . These activated MNCs may, in turn, damage the vessel wall and myocardium through production of reactive oxygen species, proteolytic enzymes and inflammatory cytokines (5,6). Thus, MIP-1␣ knock-out mice do not develop cardiac lesions after Coxsackie virus B infection because of attenuated myocardial recruitment of activated MNCs (18) . We have recently demonstrated high levels of MIP-1␣ and one of the corresponding receptors (i.e., CCR1) in the human myocardium, with particularly enhanced gene expression of CCR1 in CHF (9) . If the enhanced levels of MIP-1␣ and its receptors also exist in MNCs infiltrating the failing myocardium, our findings suggest a potential for interactions between the myocardium and MNCs in CHF involving chemokines, possibly both directly and indirectly modulating cardiac function.
Intravenous immunoglobulin down-regulates enhanced chemokine and chemokine receptor expression in CHF.
Currently, IVIg is widely used in patients with various inflammatory disorders (13) (14) (15) . How these disorders are modulated by IVIg is poorly understood, but several nonmutually exclusive modes of action may exist, such as Fc-receptor blockade, complement inactivation and cytokine modulation (13, 16) . Our study shows that modulation of chemokine expression may also represent an important mechanism of action of IVIg. The capacity to control activation and movement of inflammatory cells suggests that chemokines and their receptors might provide novel targets for therapeutic intervention in a number of diseases characterized by chronic inflammation. A series of chemokine antagonists have been found to be effective in preventing the development of various inflammatory diseases in animal models (19) . Our observation that IVIg down-regulates several chemokines and their corresponding receptors in patients with CHF, accompanied by improved LVEF, may introduce IVIg as a potential novel therapeutic modality for CHF and other cardiovascular disorders in which enhanced chemokine activity may play a pathogenic role (e.g., myocarditis and unstable angina) (5, 11, 20) . However, although the present study suggests a potential role for chemokines in the pathogenesis of CHF, a small number of patients were studied, and the effect of IVIg on the chemokine network in patients with CHF will have to be confirmed in future studies.
Conclusions. The present study demonstrates markedly altered gene expression of chemokine and chemokine receptor in MNCs from patients with CHF, and as for MIP-1␣ and MIP-1␤ and their corresponding receptors, enhanced expression was significantly correlated with depressed LVEF. Notably, these chemokine abnormalities were significantly modulated in a normal direction during IVIg therapy, concomitant with a significant improvement of LVEF. Our findings further support a role for chemokines in the pathogenesis of CHF and suggest that IVIg may represent a novel therapeutic approach, with the potential to improve LVEF in patients with CHF, at least partly by modulatory effects on the chemokine network.
